-
Posted by
Two Blokes Jul 17 -
Filed in
Stock
-
3 views
Swiss pharmaceutical giant Novartis has raised its full-year earnings forecast, citing robust revenue growth from key products, including its breast cancer drug Kisqali, during a strong second quarter. The company also announced a substantial share buyback program, signaling confidence in its future growth trajectory, alongside news of its long-serving Chief Financial Officer's upcoming retirement.
